Drug intelligence / Profile preview

tetracycline + furazolidone + esomeprazole

Development stage: Unknown
Lead developer: Roberts Laboratories
Modality: Small Molecules
Administration: Oral

Overview

This is a triple therapy combination used for the treatment of Helicobacter pylori infection. The regimen consists of tetracycline (an antibiotic), furazolidone (an antibiotic), and esomeprazole (a proton pump inhibitor). This combination has been studied as both a first-line therapy for H. pylori eradication and as a rescue therapy. Clinical trials have shown eradication rates of approximately 83-90% on intention-to-treat and per-protocol analyses. Side effects may include abdominal pain, nausea, vomiting, dizziness, decreased appetite, and skin rash.

Targets

NeuraminidaseBacterial RibosomeATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on tetracycline + furazolidone + esomeprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetracycline + furazolidone + esomeprazole.

Explore the full profile